

REMARKS

A check in the amount of \$108 for excess claims accompanies this preliminary amendment. Any fees that may be due in connection with this application throughout its pendency may be charged to Deposit Account No. 50-1213.

Claims 1-36 are pending.

Claims 1-7, 10, 11, 13, 15-20, and 22 are amended. Claims 1, 4-7, 10, 11, 13 and 15 are amended to correct minor typographical and spelling errors. Recitation of "pyrophosphates" in claims 1, 13, 15 and 20 finds basis in the paragraph on page 4, line 27-32, of the specification which describes the compositions comprising photosensitive agents conjugated to pyrophosphates. The amendment to claims 2 and 15 replaces the word "delta" with the symbol Δ for proper chemical nomenclature. The amendment to claim 3 replaces "R₁" and "R₂" in the structure of bisphosphonate with $\text{—R}^1\text{—}$ and $\text{—R}^2\text{—}$, respectively to render the structure chemically correct. The amendment to claim 3 also replaces "R1" with $\text{—R}^1\text{—}$ for proper nomenclature. The amendment to claim 16 replaces "R₁" and "R₂" in the structure of bisphosphonate with $\text{—R}^1\text{—}$ and $\text{—R}^2\text{—}$, respectively to render the structure chemically correct. The amendment to claim 17 corrects claim dependency error and finds basis in claim 16. The amendment to claims 18 and 19 replaces the article "A" with the article —The— for grammatical clarity. The amendment to claim 20 corrects minor typographical errors and replaces the word "delta" with the symbol Δ for proper chemical nomenclature. The amendment to claim 22 corrects a claim dependency error involving a multiple dependent claim that was dependent on other multiple dependent claims. New dependent claims 25-36 are added and find basis in claims 22-24 as originally filed.

The specification is amended to correct typographical and spelling errors and to produce grammatical clarity. In particular, the amendment to the paragraph on page 2, lines 15-23, of specification adds the inadvertently omitted preposition "to" for grammatical clarity. The amendment to the

U.S.S.N 09/905,405

Chen

PRELIMINARY AMENDMENT

paragraph on page 3, line 16-26, adds inadvertently omitted word "pyrophosphates". The amendment finds basis at page 1, line 29, of the specification. The amendment to the paragraph on page 4, line 23, replaces the word "pyrophosphonates" with the word "pyrophosphates" and finds basis in Figure 2. The amendment to the paragraph on page 8, line 4-10, replaces the word "delta" with the symbol Δ for proper chemical nomenclature. The amendment to the paragraph on page 10, line 21-32, deletes the second occurrence of the word "ultrasonic" for grammatical clarity.

No new matter has been added.


Included as an attachment is a marked-up version of the specification paragraphs and claims, per 37 CFR §1.121.

* * *

Entry of this amendment and examination of the application are respectfully requested.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By:


Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 25886-0060
Address all correspondence to:
Stephanie L. Seidman, Esq.
HELLER EHRMAN WHITE & McAULIFFE
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246
Telephone: 858 450-8400
Facsimile: 858 587-5360
email:sseidman@HEWM.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: JAMES CHEN

Serial No.: 09/905,405

Filed: July 13, 2001

For: *COMPOSITIONS AND METHODS
FOR TREATMENT OF METABOLIC
BONE DISORDERS AND BONE
METASTASES*

Art Unit: 3764

Examiner: Unassigned

ATTACHMENT TO THE PRELIMINARY AMENDMENT
MARKED UP PARAGRAPHS AND CLAIMS (37 CFR §1.121)

IN THE SPECIFICATION:

Please amend the specification as follows:

Please amend the paragraph on page 2, lines 15-23 as follows:

Although, photodynamic therapy (PDT) has received increasing interest as a mode of treatment for a wide variety of different cancers, PDT for the treatment of metastatic bone disease is underdeveloped. Furthermore, PDT is often associated with inadvertent tissue damage to normal tissue adjacent to diseased tissue to be treated. This inadvertent damage to collateral tissues is due to the nonspecific uptake of the photosensitizer by tissue the photosensitizer perfuses. Thus, a non-specific uptake of photosensitizer by bone tissue during PDT could potentially damage normal bone tissue that has been replaced by the abnormal bone formation associated with a particular disorder such as Paget's Disease.

Please amend the paragraph on page 3, lines 16-26, as follows:

One embodiment of the present invention is drawn to compositions comprising photosensitive agents conjugated to a compound selected from the group consisting of: bisphosphonates; pyrophosphonates; pyrophosphates; thiobisphosphonates; and nitrobisphosphonates. The photosensitizing agent is selected from the group consisting of- indocyanine green (ICG); methylene blue;

PRELIMINARY AMENDMENT ATTACHMENT

toluidine blue; aminolevulinic acid (ALA); chlorin compounds; phthalocyanines; porphyrins; purpurins; texaphyrins; and any other agent that absorbs light in a range of 500 nm - 1100 nm. A preferred embodiment of this invention contemplates that the photosensitizing agent is indocyanine green (ICG) and the compound conjugated to ICG is a bisphosphonate. These conjugates may be further conjugated to another ligand where the ligand is a target tissue specific antibody, peptide or polymer.

Please amend the paragraph on page 4, line 23, as follows:

Figure 2 shows the structure of [pyrophosphonate] pyrophosphate.

Please amend the paragraph on page 5, lines 14-22, as follows:

Terms as used herein are based upon their art recognized meaning and from the present disclosure should be clearly understood by the ordinary skilled artisan. For sake of clarity, terms may also have particular meaning as would be clear from their use in context. For example, transcutaneous more specifically herein refers to the passage of light through unbroken tissue. Where the tissue layer is skin or dermis, transcutaneous includes transdermal and the light source is external to the outer skin layer. Transillumination refers herein to the passage of light through a tissue layer, such as the outer [ocortex] cortex layer of an organ such as bone, where the light source is external to the organ, but internal or implanted into the subject or patient.

Please amend the paragraph on page 7, lines 9-14, as follows:

"Radiation" as used herein includes all wavelengths. Preferably, the radiation wavelength is selected to match the [wave length(s)] wavelength(s) or wavebands which excites the photosensitive compound. Even more preferably, the radiation wavelength matches the excitation wavelength of the photosensitive compound and has low absorption by the non-target cells and the rest of the intact animal, including blood proteins. For example, the preferred wavelength for ICG is the range of 750-850 nm.

Pl as am nd th paragraph on page 8, lines 4-10 as follows:

Preferred photosensitizing agents include, but are not limited to, chlorins, bacteriochlorins, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens and pro-drugs such as [Δ -aminolevulinic] Δ -aminolevulinic acid, which can produce drugs such as protoporphyrin. More preferred are: methylene blue; toluidine blue; texaphyrins; and any other agent that absorbs light in a range of 500 nm - 1100 nm. Most preferred is indocyanine green (ICG) (for example, see: WO 92/00106 (Raven *et al.*); WO97/31582 (Abels *et al.*) and Devoisselle *et al.*, SPIE 2627:100-108, 1995).

Please amend the paragraph on page 8, line 16-25 as follows:

The bisphosphonate composition also can be conjugated to specific ligands reactive with a target, such as receptor-specific ligands or immunoglobulins or immunospecific portions of immunoglobulins, permitting them to be more concentrated in a desired target cell or microorganism. The photosensitizing agent and/or a bisphosphonate composition may be further conjugated to a ligand-receptor binding pair, which includes, but is not limited to: biotin-streptavidin; chemokine-chemokine receptor; growth factor-growth factor receptor; and antigen-antibody. This conjugation may permit lowering of the required dose level since the material is more selectively [target] targeted and less is wasted in distribution into other tissues whose destruction must be avoided.

Please amend the paragraph on page 8, line 28, through page 9, line 4, as follows:

The bisphosphonate composition can be administered in a dry formulation, such as pills, capsules, suppositories or patches. The [biphosphonate] bisphosphonate composition also may be administered in a liquid formulation, either alone with water, or with pharmaceutically acceptable excipients, such as are disclosed in Remington's Pharmaceutical Sciences. The liquid formulation also can be a suspension or an emulsion. Liposomal or lipophilic formulations may be desirable. If suspensions or emulsions are utilized, suitable excipients; include water, saline, dextrose, glycerol, and the like. These

PRELIMINARY AMENDMENT ATTACHMENT

compositions may contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, antioxidants, pH buffering agents, and the like.

Please amend the paragraph on page 9, line 25, through page 10, line 4, as follows:

While not wishing to be limited by a theory, the inventor proposes that a photosensitizer agent can be substantially and selectively photoactivated in the target cells and target tissues within a therapeutically reasonable period of time and without excess toxicity or collateral damage to non-target tissues. Thus, there appears to be a therapeutic window bounded by the photosensitizer agent dosage and radiation dosage. The formation of photodegradation products of a photosensitizer agent was used as an indicator of photoactivation.

Photoactivation of a photosensitizer agent has been postulated to cause the formation of singlet oxygen, which has a cytotoxic effect. In view of the problems related to current methods of treating skeletal metastases which are palliative, the envisaged method of targeted transcutaneous PDT of patients injected with a [biphosphonate] bisphosphonate composition and subjected to a relatively low fluence rate, but high total fluence dose of irradiation is an attractive approach to the treatment of target tissues, that include neoplastic disease and infectious agents.

Please amend the paragraph on page 10, lines 5-20 as follows:

Additionally, the present invention is drawn to a method for transcutaneous therapy of skeletal metastases in a mammalian subject or patient by first administering to the subject a therapeutically effective amount of a first conjugate comprising a first member of a ligand-receptor binding pair conjugated to an antibody or antibody fragment, wherein said antibody or antibody fragment selectively binds to a target tissue antigen; and simultaneously or subsequently administering to the subject a therapeutically effective amount of a second conjugate comprising a second member of the ligand-receptor binding pair conjugated to an [biphosphonate] bisphosphonate composition or

PRELIMINARY AMENDMENT ATTACHMENT

[biphosphonate] bisphosphonate agent delivery system wherein the first member binds to the second member of the ligand-receptor binding pair. These steps are followed by irradiating or sonicating at least a portion of the subject with energy at a wavelength, waveband, or frequency absorbed by said [biphosphonate] bisphosphonate composition or [biphosphonate] bisphosphonate agent delivery system, by the product thereof, wherein said energy is provided by an energy source that is external to the subject; and wherein said light irradiation or sonication is at a low dose rate that results in the activation of said [biphosphonate] bisphosphonate composition or [biphosphonate] bisphosphonate agent delivery system.

Please amend the paragraph on page 10, lines 21-32 as follows:

While the preferred embodiment of the present invention is drawn to the use of light energy in a photodynamic therapy of skeletal tumors other forms of energy are within the scope of this invention and understandable by one of ordinary skill in the art. Such forms of energy include, but are not limited to: thermal; ultrasonic; [ultrasonic;] chemical; photo or light; microwave; ionizing, such as: x-ray, and [gamma ray;;] gamma ray; and electrical. For example, sonodynamically induced or activated [biphosphonate] bisphosphonate compositions include, but are not limited to: gallium-porphyrin complex (see: Yumita *et al.*, *Cancer Letters*, 112: 79-86, 1997); other porphyrin complexes, such as protoporphyrin and hematoporphyrin (see: Umemura *et al.*, *Ultrasonics Sonochemistry* 3: S187-S191, 1996); other cancer drugs, such as daunorubicin and adriamycin, used in the presence of ultrasound therapy (see: Yumita *et al.*, *Japan J Hyperthermic Oncology*, 3(2): 175-182, 1987).

Please amend the paragraph on page 11, lines 5-21, as follows:

The ordinary skilled artisan would be familiar with various ligand-receptor binding pairs, including those known and those currently yet to be discovered. Those known, include, but are not limited to the group consisting of: biotin-streptavidin; chemokine-chemokine receptor; growth factor-growth factor receptor; and antigen-antibody. This invention contemplates a preferred

embodiment that includes the use of biotin-streptavidin as the ligand-receptor binding pair. However, the ordinary skilled artisan would readily understand from the present disclosure that any ligand-receptor binding pair may be useful provided the ligand-receptor binding pair demonstrate a specificity for the binding by the ligand to the receptor and further provided that the ligand-receptor binding pair permit the creation of a first conjugate comprising a first member of the ligand-receptor binding pair conjugated to an antibody or antibody fragment, wherein said antibody or antibody fragment selectively binds to a target tissue antigen; and further permit the creation of a second [biphosphonate] bisphosphonate conjugate comprising a second member of the ligand-receptor binding pair conjugated to a photosensitizing agent or ultrasound sensitive agent, and further wherein the first member binds to the second member of the ligand-receptor binding pair.

Please amend the paragraph on page 11, line 22, through page 12, line 6 as follows:

A preferred embodiment of the present invention is drawn to a method where the photosensitizing agent delivery system includes a liposome delivery system consisting essentially of the bisphosphonate [composition] composition. A still further and preferred embodiment of the present invention contemplates the disclosed method where the photosensitizing agent delivery system utilizes both a liposome delivery system and a bisphosphonate composition, where each is separately conjugated to a second member of the ligand-receptor binding pair, and where the first member binds to the second member of the ligand-receptor binding pair, and more preferably where the ligand-receptor binding pair is biotin-streptavidin. This embodiment further contemplates that the bisphosphonate composition as well as the photosensitizing agent delivery system may both be specifically targeted through the selective binding to a target tissue antigen by the antibody or antibody fragment of the first member binding pair. Such dual targeting is envisioned to enhance the specificity of uptake and to increase the quantity of uptake. Though the total fluence

U.S.S.N 09/905,405

Chen

PRELIMINARY AMENDMENT ATTACHMENT

delivered to the treatment site will be variable depending on the size and nature of the treatment site, it is contemplated that the preferred total fluence delivered either internally or from an external light source will range between 30 Joules to 25,000 Joules, more preferably between 100 Joules to 20,000 Joules, and most preferably between 500 Joules to 10,000 Joules.

Please amend the paragraph on page 12, lines 25-30, as follows:

The specific dose of [biphosphonate] bisphosphonate conjugate is that which results in a concentration of active ICG sufficient to obtain a blood level between about 0.001 and 100 $\mu\text{g/ml}$. and more preferably, a dose of between about 0.01 and 10 $\mu\text{g/ml}$. However, it is well within the skill of the ordinary skilled artisan to determine the specific therapeutically effective dose using standard clinical practices and procedures.

Please amend the paragraph on page 14, line 25, through page 15, line 2 as follows:

As Paget's Disease is characterized by abnormally localized enhanced osteoclastic activity followed by abnormal bone formation of poor structural quality, this type of PDT treatment should minimize the bone pain, skeletal deformity, fractures, secondary arthritis, neurologic impairment and hearing loss. Since increased bone turnover is associated with increased serum levels of alkaline phosphatase and increased urinary excretion of [hydroxyproline] hydroxyproline, deoxypyridinoline and cross-linked N-telopeptide of type I collagen, the efficacy of the treatment may be determined by the serum levels of alkaline phosphatase and/or the urine levels of [hydroxyproline] hydroxyproline, deoxypyridinoline and cross-linked N-telopeptide of type I collagen. Usually, the success of the treatment is estimated by evaluating whether serum alkaline phosphatase has been reduced by 60% or lowered into the normal ranges.

Please amend the paragraph on page 17, line 10-17 as follows:

Since increased bone turnover is associated with increased serum levels of alkaline phosphatase and increased urinary excretion of [hydroxyproline]



PRELIMINARY AMENDMENT ATTACHMENT

hydroxyproline, deoxypyridinoline and cross-linked N-telopeptide of type I collagen, the efficacy of the treatment may be determined by the serum levels of alkaline phosphatase and/or the urine levels of [hydroxyproline] hydroxyproline, deoxypyridinoline and cross-linked N-telopeptide of type I collagen. Usually, the success of the treatment is estimated by evaluating whether serum alkaline phosphatase has been reduced by 60% or lowered into the normal ranges.

In the Claims:

Please amend claims 1-7, 10, 11, 13, 15-20 and 22, and please add claims 25-36 as follows:

1. (Amended) A pharmaceutical composition comprising a photosensitizer agent conjugated to a compound selected from the group consisting of: bisphosphonates; pyrophosphonates, pyrophosphates; thiobisphosphonates; and nitrobisphosphonates.
2. (Amended) The composition of [claim 1] claim 1, wherein the photosensitizer agent is selected from the group consisting of chlorins, bacteriochlorins, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens, benzoporphyrin derivatives (BPD), porfimer sodium, [delta-aminolevulinic] Δ-aminolevulinic acid, protoporphyrin, indocyanine green (ICG), methylene blue, toluidine blue, texaphyrins and any other agent that absorbs light in a range of 500 nm - 1100 nm.
3. (Amended) The composition of [claim 1] claim 1, wherein the compound is a bisphosphonate of the formula



PRELIMINARY AMENDMENT ATTACHMENT

wherein [R1] R^1 is independently selected from the group consisting of: hydroxyl, an amino group, -CN, -NO₂, haloalkyl, heteroaryl, phenyl, alkyl, alkoxy, alkylthio, halo and alkyl-carbonyloxy; and wherein R^2 is independently selected from the group consisting of: alkyl, aminoalkyl -CN, -NO₂, -NH₂, haloalkyl, heteroaryl, phenyl, alkyl, alkoxy, alkylthio, halo and alkyl-carbonyloxy.

4. (Amended) The composition of [claim 3] claim 3, wherein R^1 is hydroxyl or an amino group and R^2 is alkyl or aminoalkyl.
5. (Amended) The composition of [claim 3] claim 3, wherein the compound is selected from the group consisting of etidronate, tiludronate, clodronate, pamidronate, alendronate, risedronate and ibandronate.
6. (Amended) The composition of [claim 1] claim 1, further conjugated to a target tissue specific ligand.
7. (Amended) The composition of [claim 1] claim 1, further conjugated to an imaging agent.
10. (Amended) The method of [claim 8] claim 8, wherein said composition is conjugated to an imaging agent.
11. (Amended) The method of [claim 10] claim 10, further comprising the steps of performing a nuclear medicine scan and imaging the target cells or target tissues to be destroyed or impaired.
13. (Amended) A method for destroying or impairing target cells involved in disease of bone tissue in a mammalian subject comprising:
administering to the subject a therapeutically effective amount of a composition comprising a photosensitizer agent conjugated to a compound selected from the group consisting of: bisphosphonates; pyrophosphonates; pyrophosphates; thiobisphosphonates; and nitrobisphosphonates, wherein said composition selectively binds the target cells or target tissues involved in said disease of bone tissue; and
irradiating at least a portion of the subject with light at a wavelength absorbed by said composition, wherein said light is provided by a light source, and wherein said irradiation is at a relatively low fluence rate that

PRELIMINARY AMENDMENT ATTACHMENT

results in the activation of said composition, wherein said composition is cleared from non-target tissues of the subject prior to said irradiation.

15. (Amended) A method for treating a metabolic bone disorder or bone metastases in a mammalian subject comprising:



administering to the subject a therapeutically effective amount of a composition comprising

a photosensitizer agent selected from the group consisting of chlorins, bacteriochlorins, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens, benzoporphyrin derivatives (BPD), porfimer sodium, [delta-aminolevulinic] Δ -aminolevulinic acid, protoporphyrin, indocyanine green (ICG), methylene blue, toluidine blue, texaphyrins and any other agent that absorbs light in a range of 500 nm - 1100 [nm] nm,

which is conjugated to a compound selected from the group consisting of bisphosphonates; pyrophosphonates; pyrophosphates; thiobisphosphonates; and nitrobisphosphonates which selectively binds the target tissues or cells involved in the metabolic bone disorder or bone metastases and said composition is further conjugated to an imaging agent; and performing a nuclear medicine scan;

imaging the target tissues or cells to be treated; and irradiating at least a portion of the subject with light at a wavelength absorbed by said composition, wherein said light is provided by a light source, and wherein said irradiation is at a relatively low fluence rate that results in the activation of said composition, wherein said composition is cleared from non-target tissues of the subject prior to said irradiation.

16. (Amended) A method for destroying or impairing target cells involved in disease of bone tissue in a mammalian subject according to claim 13 or 15, wherein said compound is a bisphosphonate of the formula



wherein R¹ is independently selected from the group consisting of: hydroxyl, an amino group, -CN, -NO₂, haloalkyl, heteroaryl, phenyl, alkyl, alkoxy, alkylthio, halo and alkyl-carboxyloxy; and wherein R² is independently selected from the group consisting of: alkyl, aminoalkyl -CN, -NO₂, -NH₂, haloalkyl, heteroaryl, phenyl, alkyl, alkoxy, alkylthio, halo and alkyl-carboxyloxy.

17. (Amended) The method according to [claim 13 or 15] claim 16, wherein R¹ is hydroxyl or an amino group and R² is alkyl or aminoalkyl.

18. (Amended) [A] The method according to claim 13 or 15, wherein the compound is selected from the group consisting of etidronate, tiludronate, clodronate, pamidronate, alendronate, risedronate and ibandronate.

19. (Amended) [A] The method according to claim 13 or 15, wherein the composition is conjugated to a target tissue specific ligand or an imaging agent.

20. (Amended) A method for destroying or impairing target cells involved in disease of bone tissue in a mammalian subject comprising:

administering to the subject a therapeutically effective amount of a composition comprising a photosensitizer agent, wherein said agent is selected from the group consisting of chlorins, bacteriochlorins, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens, benzoporphyrin derivatives (BPD), porfimer sodium, [delta-aminolevulinic] Δ-aminolevulinic acid, protoporphyrin, indocyanine green (ICG), methylene blue, toluidine blue,

PRELIMINARY AMENDMENT ATTACHMENT

texaphyrins and any other agent that absorbs light in a range of 600 nm -1100 nm, and wherein said agent is conjugated to a compound selected from the group consisting of: bisphosphonates; pyrophosphonates; pyrophosphates; thiobisphosphonates; and nitrobisphosphonates; and wherein said composition selectively binds the target cells or target tissues involved in said disease of bone tissue; and irradiating at least a portion of the subject with light at a wavelength absorbed by said composition, wherein said light is provided by a light source, and wherein said irradiation is at a relatively low fluence rate that results in the activation of said composition; and

wherein said composition is cleared from non-target cells or non-target tissues of the subject prior to said irradiation.

22. (Amended) The method of any one of [claims 8-21] claims 9-15, 17, 20 and 21, wherein said fluence rate results in the irradiating of said subject with a total fluence of irradiation delivered either internally or from an external light source at a range of about between 30 Joules/cm² to 25,000 Joules/cm².